docid|entityid|type
0|Early Phase Clinical Trial|Topic
0|Phase I Trials|Topic
0|Cytotoxic Agents|Topic
0|Bayesian Early Phase Trial Designs|Topic
0|Peter F. Thall|Author
1|Deep Historical Borrowing Framework To Prospectively And Simultaneously Synthesize Control Information In Confirmatory Clinical Trials With Multiple Endpoints|Paper
1|Tianyu Zhan|Author
1|Yiwang Zhou|Author
1|Ziqian Geng|Author
1|Yihua Gu|Author
1|Jian Kang|Author
1|Li Wang|Author
1|Xiaohong Huang|Author
1|Elizabeth H. Slate|Author
2|Pilot Studies Of Structured Treatment Interruptions In Hiv Therapy|Topic
2|Hiv Therapy|Topic
2|Virologic Failure|Topic
2|Novel Hypothesis|Topic
2|Mathematical Model Of Hiv Within-Host Viral Dynamics|Topic
2|Nonlinear Parametric Resonance|Topic
2|Clinical Trial Data|Topic
2|Patient-Specific Resonant Spectra|Topic
2|Immunologic And Virologic Parameters|Topic
2|Romulus Breban|Author
2|Sally Blower|Author
3|Preventive Vaccines|Topic
3|Hiv|Topic
3|Immune Response Markers|Topic
3|Two-Phase Sampling|Topic
3|Txshift R Package|Topic
3|Nima S. Hejazi|Author
3|Mark J. Van Der Laan|Author
3|Holly E. Janes|Author
3|Peter B. Gilbert|Author
3|David C. Benkeser|Author
4|Phase 1-2 Designs|Topic
4|Generalized Phase 1-2 Design|Topic
4|Biological Outcome|Topic
4|Therapeutically Optimal Dose|Topic
4|Cheng-Han Yang|Author
4|Peter F. Thall|Author
4|Ruitao Lin|Author
4|Simulation Study|Topic
5|Align|Topic
5|Nabeel Seedat|Author
5|Caterina Tozzi|Author
5|Andrea Hita Ardiaca|Author
5|Mihaela Van Der Schaar|Author
5|James Weatherall|Author
5|Adam Taylor|Author
5|Large Language Models|Topic
5|Anatomical Therapeutic Chemical|Topic
5|Medical Dictionary For Regulatory Activities|Topic
6|Ross M. Kedl|Author
6|Sars-Cov2 And Variants Of Concern|Topic
6|Moderna Phase Iii Clinical Trial|Topic
6|Longitudinal Evaluation Of T And B Cell Immunity|Topic
6|Covid-19 Vaccine Trial Participant|Topic
6|Anecdote|Topic
7|Sleep Monitoring Algorithm|Topic
7|Polysomnography|Topic
7|Sleep Apnea Detection|Topic
7|Hao He|Author
7|Chao Li|Author
7|Wolfgang Ganglberger|Author
7|Kaileigh Gallagher|Author
7|Rumen Hristov|Author
7|Michail Ouroutzoglou|Author
7|Haoqi Sun|Author
7|Jimeng Sun|Author
7|Brandon Westover|Author
7|Dina Katabi|Author
8|Vaccine Efficacy Estimands|Topic
8|Mats Stensrud|Author
8|Daniel Nevo|Author
8|Uri Obolski|Author
8|Influenza Vaccine Trial|Topic
9|Panacea|Topic
9|Trialalign|Topic
9|Trialinstruct|Topic
9|Trialpanorama|Topic
9|Jiacheng Lin|Author
9|Hanwen Xu|Author
9|Zifeng Wang|Author
9|Sheng Wang|Author
9|Jimeng Sun|Author
10|Immune Correlates Of Protection|Topic
10|Correlates Of Risk|Topic
10|Controlled Vaccine Efficacy Curve|Topic
10|Controlled-Risk Curve|Topic
10|50% Neutralizing Antibody Titer|Topic
10|Virologically Confirmed Dengue|Topic
10|Peter B. Gilbert|Author
10|Youyi Fong|Author
10|Marco Carone|Author
10|Cyd14|Paper
10|Cyd15|Paper
11|Rank-Based Identification Of High-Dimensional Surrogate Markers: Application To Vaccinology|Paper
11|Arthur Hughes|Author
11|Layla Parast|Author
11|Rodolphe Thi√©baut|Author
11|Boris P. Hejblum|Author
11|Surrogate Markers|Topic
11|Vaccine Trials|Topic
11|High-Throughput Technologies|Topic
11|Rise|Topic
12|Trial2Vec|Topic
12|Zifeng Wang|Author
12|Jimeng Sun|Author
12|Clinical Trials|Topic
12|Umls Knowledge Base|Topic
13|Spot|Topic
13|Zifeng Wang|Author
13|Cao Xiao|Author
13|Jimeng Sun|Author
13|Clinical Trials|Topic
14|Matrix-Valued Time-Series Data Clustering|Topic
14|Low-Dimensional Embedding|Topic
14|Static Clinical Covariates|Topic
14|High-Dimensional Longitudinal Features|Topic
14|Sparse And Irregular Nature Of Sample Collection|Topic
14|Smoothed Probabilistic Parafac Model With Covariates (Spaco)|Paper
14|Immunological Data Set From Patients With Sars-Cov-2 Infection|Topic
15|World Health Organization|Topic
15|Hiv Treatment|Topic
15|Resource-Limited Settings|Topic
15|Clinical And Immunological Markers|Topic
15|Cd4 Cell Counts|Topic
15|Viral Load|Topic
15|Diagnostic Algorithm|Topic
15|Miriam Hospital Immunology Clinic|Topic
15|Tao Liu|Author
15|Joseph W. Hogan|Author
15|Lisa Wang|Author
15|Shangxuan Zhang|Author
15|Rami Kantor|Author
15|Optimal Allocation Of Gold Standard Testing Under Constrained Availability: Application To Assessment Of Hiv Treatment Failure|Paper
16|Clinical Trial Outcome (Cto) Knowledge Base|Topic
16|Chufan Gao|Author
16|Jathurshan Pradeepkumar|Author
16|Trisha Das|Author
16|Shivashankar Thati|Author
16|Jimeng Sun|Author
16|Clinical Trial Outcomes|Topic
16|Drug Discovery And Development|Topic
17|Clinical Trials|Topic
17|Nlp|Topic
17|Eligibility Classification|Topic
17|Phase 3 Cancer Trials|Topic
17|Non-Cancer Trials|Topic
17|Phase 1 And 2 Cancer Trials|Topic
17|Heart Disease Trials|Topic
17|Type 2 Diabetes Trials|Topic
17|Observational Trials|Topic
17|Yumeng Yang|Author
17|Ashley Gilliam|Author
17|Ethan B Ludmir|Author
17|Kirk Roberts|Author
17|Annotated Eligibility Criteria Dataset|Topic
18|Trialsynth|Topic
18|Chufan Gao|Author
18|Mandis Beigi|Author
18|Afrah Shafquat|Author
18|Jacob Aptekar|Author
18|Jimeng Sun|Author
18|Variational Autoencoder|Topic
18|Hawkes Processes|Topic
18|Synthetic Time-Sequence Clinical Trial Data|Topic
18|Clinical Trials|Topic
18|Patient Privacy|Topic
18|Adverse Events|Topic
18|Event Sequences|Topic
18|Real-World Sequential Event Datasets|Topic
18|Fidelity / Privacy Tradeoff|Topic
19|Ct-Bert|Topic
19|Natural Language Processing (Nlp) Of Clinical Trial Documents|Topic
19|Xiong Liu|Author
19|Greg L. Hersch|Author
19|Iya Khalil|Author
19|Murthy Devarakonda|Author
19|Named Entity Recognition (Ner) Models|Topic
19|Attention-Based Bilstm|Topic
19|Criteria2Query|Topic
20|Ctp-Llm|Topic
20|Phasetransition Dataset|Topic
20|Michael Reinisch|Author
20|Jianfeng He|Author
20|Chenxi Liao|Author
20|Sauleh Ahmad Siddiqui|Author
20|Bei Xiao|Author
21|Machine Learning|Topic
21|Clinical Domain|Topic
21|Data Scarcity|Topic
21|Ethical Considerations|Topic
21|Clinical Trials|Topic
21|Privacy Regulations|Topic
21|High Costs|Topic
21|Extended Duration|Topic
21|Large Language Models|Topic
21|Retrieval-Reasoning Few-Shot Framework|Topic
21|Synthetic Clinical Trials|Topic
21|Binary Success/Failure Labels|Topic
21|Clinicaltrials.Gov|Topic
21|Synthetic Data|Topic
21|Pre-Trained Model|Topic
21|Binary Classifier|Topic
21|Trial Outcome Prediction|Topic
21|Zerui Xu|Author
21|Fang Wu|Author
21|Yuanyuan Zhang|Author
21|Yue Zhao|Author
21|Code|Topic
21|Https://Anonymous.4Open.Science/R/Retrieval_Reasoning_Clinical_Trial_Generation-3Ec4|Topic
22|Clinical Trials|Topic
22|Drug Development|Topic
22|Phase I|Topic
22|Phase Ii|Topic
22|Phase Iii|Topic
22|Phase Iv|Topic
22|Challenges In Clinical Trials|Topic
22|Innovative Technologies|Topic
22|Emerging Therapies|Topic
22|Regulatory Reforms|Topic
22|Global Collaboration|Topic
22|From Bench To Bedside: A Review Of Clinical Trials In Drug Discovery And Development|Paper
22|Tianyang Wang|Author
22|Ming Liu|Author
22|Benji Peng|Author
22|Xinyuan Song|Author
22|Charles Zhang|Author
22|Xintian Sun|Author
22|Qian Niu|Author
22|Junyu Liu|Author
22|Silin Chen|Author
22|Keyu Chen|Author
22|Ming Li|Author
22|Pohsun Feng|Author
22|Ziqian Bi|Author
22|Yunze Wang|Author
22|Yichao Zhang|Author
22|Cheng Fei|Author
22|Lawrence Kq Yan|Author
23|Bayesian Adaptive Designs|Topic
23|Clinical Trials|Topic
23|Covid-19 Pandemic|Topic
23|Shirin Golchi|Author
23|Efficient Estimation And Uncertainty Quantification|Topic
23|Design Operating Characteristics|Topic
23|Sampling Distribution Of Bayesian Probability Statements|Topic
23|Ordinal Disease-Progression Scale Endpoint|Topic
23|Clinical Trial Design|Topic
24|Artificial Intelligence For In Silico Clinical Trials: A Review|Paper
24|Zifeng Wang|Author
24|Chufan Gao|Author
24|Lucas M. Glass|Author
24|Jimeng Sun|Author
24|Clinical Simulation|Topic
24|Individualized Predictive Modeling|Topic
24|Computer-Aided Trial Design|Topic
25|Clinical Trial Outcome Prediction|Topic
25|Language Interaction Network (Lint)|Topic
25|Chufan Gao|Author
25|Tianfan Fu|Author
25|Jimeng Sun|Author
25|Biologics|Topic
25|Machine Learning Models|Topic
25|Roc-Auc Scores|Topic
25|Clinical Trials|Topic
25|Drug Portfolio|Topic
25|Small-Molecule Drugs|Topic
25|Graph Neural Networks|Topic
25|Phases I, Ii, And Iii|Topic
26|Rats|Topic
26|Random Dot Motion Task|Topic
26|Stimulus Integration|Topic
26|Trial Difficulty|Topic
26|Reward-Related Parameters|Topic
26|Pamela Reinagel|Author
26|Emily Mankin|Author
26|Adam Calhoun|Author
27|A Latent Gaussian Process Model With Application To Monitoring Clinical Trials|Paper
27|Yanxun Xu|Author
27|Yuan Ji|Author
27|Bayesian Trial Monitoring Scheme|Topic
27|Latent Gaussian Process (Lgp)|Topic
28|Clinical Trial Site Matching With Improved Diversity Using Fair Policy Learning|Paper
28|Clinical Trials|Topic
28|Diversity And Inclusion|Topic
28|Feasibility|Topic
28|Fairness In Machine Learning|Topic
28|Demographic Parity|Topic
28|Patient Groups|Topic
29|Ongoing Vaccine And Monoclonal Antibody Hiv Prevention Efficacy Trials And Considerations For Sequel Efficacy Trial Designs|Paper
29|Hvtn 702|Topic
29|Hvtn 705|Topic
29|Hvtn 703/Hptn 081|Topic
29|Hvtn 704/Hptn 085|Topic
29|Hiv-1|Topic
29|Statistical Science Considerations|Topic
29|Correlates Of Protection|Topic
29|Monoclonal Antibody Trials|Topic
